Laidlaw initiated coverage of Senti Bio (SNTI) with a Buy rating and $5 price target Senti is an early clinical stage oncology-emphasized biotech company that focuses on a novel and differentiated CAR-NK therapy, SENTI-202, as a potential high-risk relapsed or refractory acute myeloid leukemia treatment, the analyst tells investors in a research note. The firm says the company recently reported “very promising” Phase I interim results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNTI: